Kane Biotech (KNE) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 was $27,997, a sharp decline from $620,437 in Q2 2024, mainly due to the sale of the animal health business in 2024.

• Net loss narrowed to $348,541 in Q2 2025 from $1,215,996 in Q2 2024.

• Three new directors joined the board, and key board roles were reassigned to enhance governance.

Financial highlights

• Gross loss of $45,526 in Q2 2025, compared to a gross profit of $360,490 in Q2 2024.

• Operating expenses dropped to $229,930 from $1,463,397 year-over-year, driven by staff reductions, bonus reversals, and lower R&D costs.

Outlook and guidance

• Ongoing clinical case series in the US expected to generate new data and be presented at future conferences in 2025 and 2026.

• Efforts underway to build new US distributor networks following termination of a prior agreement.